))
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Manage episode 390589137 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
48 episodes
Partager
